Meeting
2019 ASCO Annual Meeting
Molecular biomarker analysis and survival in patients (pts) with advanced urothelial cancer (UC) previously treated with chemotherapy.
Authors
Bernadett Szabados
Barts Cancer Centre, Queen Mary University of London, London, United Kingdom
Bernadett Szabados , Marlon Rebelatto , Craig Barker , Alvin Milner , Arthur Lewis , Michael Stokes , Magda Zajac , Thomas Powles , Norah J Shire
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT00949455
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4529)
DOI
10.1200/JCO.2019.37.15_suppl.4529
Abstract #
4529
Poster Bd #
355
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Exploratory evaluation of baseline tumor biomarkers and their association with response and survival in patients with previously treated advanced gastric cancer treated with andecaliximab combined with nivolumab versus nivolumab.
First Author: Jean-Philippe Metges
Poster
2016 ASCO Annual Meeting
Correlation of PD-L1 expression with immune cell infiltrates, genome-wide copy number aberrations and survival in mesothelioma.
First Author: Bibhusal Thapa
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Updated pooled analyses of first-line anti-PD1/PD-L1 inhibitors plus chemotherapy in advanced esophageal squamous cell carcinoma.
First Author: Maysa Vilbert
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Benefit of immune checkpoint inhibitors (ICI) for patients with advanced esophageal squamous cell carcinoma and low PD-L1 expression: A systematic review and meta-analysis.
First Author: Mario Machado Lopes